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BACKGROUND AND PURPOSE
Cucurbitacin R, a natural anti-inflammatory product, has been shown to exhibit activity against both adjuvant-induced
arthritis and delayed-type hypersensitivity reactions induced by various agents. Previous studies have demonstrated that the
effects of cucurbitacin R stem from its inhibition of both cytokine production and lymphocyte proliferation.
EXPERIMENTAL APPROACHES
Effects of cucurbitacin R were investigated on lipopolysaccharide-stimulated RAW 264.7 cells. Cell cycle evolution was
analysed by flow cytometry, detection of apoptosis by DNA ladder, Bcl-2, p21, p53, Bax, cleaved caspase-1 (p10), caspase-9,
and caspase-3, cleaved caspase (p17) and interleukin-1b detection was followed by Western blot analysis and mRNA
expression with quantitative real time reverse transcription-polymerase chain reaction (qRT-PCR).
KEY RESULTS
Cucurbitacin R was found to induce apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages through the
inhibition of Bcl-2 expression, which regulates pro-inflammatory caspase-1 activation and interleukin-1b release. Also,
cucurbitacin R arrested the cell cycle in the G2/M phase and increased the subG0 population in lipopolysaccharide-stimulated
RAW 264.7 macrophages. Moreover, it increased the expression of proteins p53 and p21, down-regulated the expression of
Bcl-2, activated the activity of caspase-1 and augmented the production of interleukin-1b. Finally, the transfection of RAW
264.7 macrophages with a Bcl-2 expression plasmid produced the inhibition of apoptosis and caspase-1
activation/interleukin-1b release induced by cucurbitacin R in RAW 264.7 cells.
CONCLUSIONS AND IMPLICATIONS
Taken together, these results point to a new apoptotic process in which interleukin-1b release is directly regulated by Bcl-2
status; this contributes to the evidence that apoptotic processes do not induce inflammation.
Abbreviations
IkB, inhibitor protein of NF-kB; IKK, IkB kinase; JAK2, Janus kinase-2; MTT,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NALP1 (nucleotide-dependent activator of
cytokine-processing protease caspase-1; NF-kB, nuclear factor-kB; PAI, plasminogen activator; qRT-PCR, quantitative
reverse transcription-polymerase chain reaction; STAT3, signal transducer and activator of transcription-3; TNF-a,
tumour necrosis factor-a
BJP British Journal ofPharmacology
DOI:10.1111/j.1476-5381.2010.00856.x
www.brjpharmacol.org
1844 British Journal of Pharmacology (2010) 160 1844–1856 © 2010 The Authors
Journal compilation © 2010 The British Pharmacological Society
Introduction
Cucurbitacins are a group of natural products with a
triterpene skeleton that are present in different
plant species, especially those of the Cucurbitaceae
and Cruciferae, which have been used as folk medi-
cines for centuries in countries such as China and
Brazil. However, only a small number of their phar-
macological activities have been reported to date,
notably their role as antagonists of ecdysteroids and
their influence on the growth and development of
insects (Ríos et al., 2005). Several cucurbitacins have
also been shown to have anti-inflammatory and
cytotoxic effects (Ríos et al., 2005). In previous
papers, we have described the anti-inflammatory
(Recio et al., 2004) and anti-arthritic (Escandell
et al., 2007a) properties of cucurbitacin R. Indeed, in
the latter study Escandell et al. (2007a) affirmed that
the anti-arthritic effect of cucurbitacin R was due to
its inhibition of signal transducer and activator of
transcription-3 (STAT3) activation and the reduc-
tion of tumour necrosis factor-a (TNF-a). In parallel,
the induction of nitric oxide synthase was inhibited
along with nitric oxide production. However,
while prostaglandin E2 production decreased,
cyclooxygenase-2 induction did not. Taken
together, these results suggest that cucurbitacin R
could be a potential anti-inflammatory agent that
acts through a mechanism in which the inhibition
of TNF-a in lymphocytes is implicated, as is the
activation of Janus kinase-2 and STAT3, as previ-
ously demonstrated by Sun et al. (2005) for other
closely related compounds.
Recently, Escandell et al. (2008) demonstrated
that cucurbitacins induced dramatic changes in the
cytoskeleton of the cell, inhibiting cell proliferation
in the G2/M phase and inducing apoptosis of both
HCT116 and Hke-3 cells. However, the presence of
oncogenic kRas clearly decreased the sensitivity of
the cells to the three cucurbitacins tested, cucurbi-
tacin R, dihydrocucurbitacin B and cucurbitacin I.
Cucurbitacins also induced the expression of p53
and p21 in HCT116 cells harbouring mutant Ras.
Using HCT116 cells with targeted deletion of p53 or
p21, we confirmed that p53 and p21 actually protect
cells from cucurbitacin-induced apoptosis.
Apoptosis is a physiological process critical for
the development, homeostasis and normal func-
tioning of the immune system. It involves the
removal of cells from tissues in a deliberate and
systematic manner, supposedly without an inflam-
matory reaction. Different proteins and enzymes are
involved in the initiation, amplification and sup-
pression of apoptosis, but it is generally caspases
that mediate the final process of cell death (Wu and
Shi, 2007). Caspases are intracellular proteases that
cleave the substrates involved in both apoptosis and
inflammation. They are expressed as inactive pre-
cursors or procaspases and are triggered into action
as a result of their proteolytic processing at con-
served aspartic acid residues to give rise to the active
form (Wu and Shi, 2007). Although cell death can
occur through caspase-independent, non-apoptotic
mechanisms, the morphological characteristics that
define the process of apoptosis still depend on
caspases (Bleackley and Heibein, 2001).
Interleukin-1b, one of the major caspase-1
targets, is a multifunctional cytokine that is
involved in a host of immune and pro-
inflammatory responses (Dinarello, 1998). It is pro-
duced primarily by activated monocytes and
macrophages, and signals through various adaptor
proteins and kinases that lead to the activation of
numerous downstream targets (Cao et al., 1996a,b).
Human interleukin-1b is synthesized as a 35 kDa
precursor. To gain activity, the precursor must be
cleaved by caspase-1 between Asp116 and Ala117 to
yield a 17 kDa mature form (Cerretti et al., 1992;
Thornberry et al., 1992). Detection of the 17 kDa
mature form of interleukin-1b is a good indicator of
the activity of the interleukin-1b converting
enzyme, better known as caspase-1, which is
required for this cleavage (Cerretti et al., 1992;
Thornberry et al., 1992; Alnemri et al., 1996).
Various agents, including lipopolysaccharide, are
known to strongly induce the activation of
caspase-1.
Recently, Bruey et al. (2007) identified a new
mechanism for controlling caspase activation. They
demonstrated that the anti-apoptotic proteins Bcl-2
and Bcl-XL interact with NALP1 (a nucleotide-
dependent activator of cytokine-processing protease
caspase-1), suppressing the NALP1-mediated activa-
tion of pro-inflammatory caspases and reducing
interleukin-1b production. In addition, Greten et al.
(2007) demonstrated that the inhibitor protein of
NF-kB (IkB) kinase-b (IKKb) inhibition produced
an increase in both caspase-1 activation and
interleukin-1b production.
In the present study, we have focused on the
apoptosis induced by cucurbitacin R in RAW 264.7
macrophages to determine how these apoptotic pro-
cesses can affect not only the release of different
inflammatory mediators such as interleukin-1b but
also their possible regulation by Bcl-2.
Methods
Chemicals and cell lines
Cucurbitacin R (Figure 1) was previously obtained
from tayuya roots (Recio et al., 2004). RAW 264.7
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macrophages were maintained in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% fetal
calf serum and antibiotics, and propagated by scrap-
ping. All biochemicals and chemicals were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA).
Specific antibodies for b-actin were also obtained
from Sigma-Aldrich, and antibodies recognizing
caspase-3, p53, Bcl-2, Bax and p21 were purchased
from Santa Cruz Biotechnologies (Santa Cruz, CA,
USA).
Detection of apoptosis by DNA ladder in
RAW 264.7 macrophages
Their viability was assessed with the aid of the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. First, cells were placed into
each well of a 24-well flat-bottomed plate (Nunc,
Raskilde, Denmark) with or without 1 mg·mL-1
lipopolysaccharide. Cucurbitacin R (100–12.5 mM)
was added to the cells and the plates were incubated
in 5% CO2-air humidified atmosphere at 37°C for
different time periods. The cells were collected by
means of centrifugation, and the pellet was resus-
pended in lysis buffer (100 mM EDTA, 10 mM Tris-
HCl). Then, 10% SDS and 100 mg·mL-1 proteinase K
were added to the homogenate, which was subse-
quently incubated for 1 h at 50°C. Proteins were
precipitated through addition of 5 M NaCl, and the
samples were centrifuged at 20 000 g for 15 min.
The supernatant was mixed with an equal volume of
phenol-chloroform-isoamylalcohol (25:24:1) and
centrifuged at 20 000 g for 15 min. The uppermost
layer was collected in a new vial, mixed with an
equal volume of chloroform-isoamylalcohol (24:1)
and centrifuged at 20 000 g for 5 min. Finally, the
newly formed uppermost layer was mixed with
2-propanol, 10 mM MgCl2, and 10% glycogen (1 mL)
and placed on ice for 15 min. DNA fragments were
collected from this layer. To these fragments, 70%
ethanol was added and the mixture was centrifuged
at 20 000 g for 10 min. The desiccated pellet of DNA
fragments was then dissolved in 25 mL of Tris-EDTA
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.4). Con-
taminating RNA was removed by incubating the
samples with RNAase A (1 mg·mL-1) at 37°C for
20 min. Purified DNA (1 mg) was submitted to
electrophoresis on a 2% agarose gel. The gel was
stained with 0.5 mg·mL-1 ethidium bromide solu-
tion (Sigma-Aldrich), viewed on a UV transil-
luminator (LAS 3000 mini, Fuji, Tokyo, Japan) and
photographed.
Cell cycle analysis
In order to analyse the cell cycle and apoptosis in
RAW 264.7 macrophages, cells were first adjusted to
a final concentration of 1 ¥ 106 cells·mL-1 before use
and then 1 mL of cell suspension was placed into
each well of a six-well flat-bottomed plate (Nunc)
with or without lipopolysaccharide (1 mg·mL-1) after
treatment with the products. First, various concen-
trations of cucurbitacin R (100–12.5 mM) were added
to the cells and the plates were incubated in 5%
CO2-air-humidified atmosphere at 37°C for different
time periods up to 24 h. In this experiment, we were
looking for the subG0 peak as an index of apoptosis,
and then for the G1, G2 and S peaks. The cells were
harvested by means of centrifugation, washed in
phosphate-buffered saline (pH 7.2) and then fixed in
70% ethanol for 30 min at -20°C. After the cells had
been washed once with phosphate-buffered saline,
the DNA was stained with propidium iodide
(4 mg·mL-1, containing 100 mg·mL-1 of ribonuclease
A; Sigma-Aldrich). Flow cytometry was carried out
on a Beckman Coulter EPICS XCL (Fullerton, CA,
USA); 104 cells were counted for each test sample.
Cell cycle histograms were analysed with the aid
of the Cylchred program (University of Wales,
College of Medicine, Cardiff, UK).
Annexin V apoptosis assay and
determination of mitochondrial
membrane potential
The detection of phosphatidylserine on the cell
surface of the macrophages was performed with an
Annexin V-fluorescein isothiocyanate apoptosis
detection kit (BD PharMingen, San Diego, CA, USA),
in accordance with the manufacturer’s instructions.
Briefly, unstimulated and lipopolysaccharide-
stimulated cells (1 ¥ 106 cells·mL-1) were cultured in
24-well flat-bottomed plates and subsequently
exposed (or not) to cucurbitacin R (100-12.5 mM) for
different time periods. The cells were collected by
scrapping, washed with cold phosphate-buffered
saline and resuspended in binding buffer. The cells
were then stained with Annexin V-fluorescein
isothiocyanate and propidium iodide. After a
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Figure 1
Chemical structure of cucurbitacin R.
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30-min incubation period, the cells were analysed
with the aid of flow cytometry.
Mitochondrial membrane potential was deter-
mined by means of flow cytometry through double
staining with dihydrorhodamine 123 and pro-
pidium iodide. Lipopolysaccharide-stimulated cells
were treated at different concentrations of cucurbi-
tacin R for 18 h and stained with 1 mM of dihydror-
hodamine 123 and propidium iodide for 1 h at
37°C, washed with phosphate-buffered saline, and
analysed by the use of fluorescence techniques in
the FL1 and FL3 channels of a flow cytometry Epics
XL-MCL device (Beckman).
Analysis of caspase-3 and caspase-1 activity
The activity of caspase-3 was determined by the use
of the cell-permeable fluorogenic substrate
(EnzoLyte™ AMC Capase-3 Assay Kit, Anaspec, San
Jose, CA, USA), which was used according to the
manufacturer’s instructions. The activity of
caspase-1 was also determined with a cell-permeable
fluorogenic specific substrate, also used according to
the manufacturer’s instructions. The activity was
quantified by measuring fluorescence intensity
upon caspase-3 or caspase-1 cleavage at Ex/Em =
354 nm/442 nm. Macrophages (1 ¥ 106 cells·mL-1)
were cultured in a 96-well black tissue culture micro-
plate and treated with either cucurbitacin R
(100 mM) or Ac-DEVD-CHO (10 mM). They were
then stimulated with lipopolysaccharide for 24 h.
Caspase-3 (peptide sequence = Ac-Asp-Glu-Val-Asp-
AMC) substrate or caspase-1 (Ac-YVAD-AMC) was
added to the cells, and the fluorescence was mea-
sured with a Victor Fluorescence microplate reader
(Perkin Elmer, Wellesley, MA, USA).
Transient and stable transfections
Cells were transfected with a pool of siRNA specific
for caspase-1 or non-specific siRNA (Dharmacon,
Chicago, IL, USA) with the aid of lipofectamine
2000 (Invitrogen, Langley, OK, USA). Bcl-2 and
PAI-2 expression plasmids or empty vector were also
transfected with lipofectamine 2000 and selected by
G418.
Quantitative reverse transcription-polymerase
chain reaction (RT-PCR)
RAW 264.7 macrophages (1 ¥ 106 cells·mL-1) were
treated with cucurbitacin R at 100 mM for 8 h, after
which the RNA was extracted with the aid of RNeasy
mini spin (50) columns (Qiagen, Hilden, Germany).
Real time RT-PCR was performed using a one-step
qRT-PCR kit (Invitrogen, Paisley, UK) following the
manufacturer’s instructions. Applied biosystems
(Foster City, CA, USA) 7500 qPCR platform was
used. Results are expressed in time fold expression of
interleukin-1b using GAPDH (R&D Systems, Minne-
apolis, MN, USA) as a housekeeping gene.
Western blot analysis
Cellular lysates from RAW 264.7 macrophages incu-
bated for different periods of time with cucurbitacin
R (100 mM) and lipopolysaccharide were obtained as
described previously by Escandell et al. (2007a). For
Bcl-2, p21, p53, Bax, cleaved caspase-1 (p10),
caspase-3, cleaved caspase-3 (p17) (Cell Signalling,
Danvers, MA, USA), caspase-9 (Cell Signalling),
NALP1 (Cell Signalling) and interleukin-1b (R&D
Systems) the membranes were incubated with the
respective polyclonal antibodies (1:200 dilution,
Santa Cruz). For b-actin, the membranes were incu-
bated with monoclonal antibody (1:10 000 dilution,
Sigma-Aldrich).
For Western blot of interleukin-1b in superna-
tants, 50 mL of media were collected at different time
points from the LPS- or cucurbitacin R (100 mM)-
treated RAW macrophages, and Western blot was
carried out as described before.
Interleukin-1b production in RAW
264.7 macrophages
Macrophages (RAW 264.7) at 1 ¥ 106 cells·mL-1 were
co-incubated in a 96-well culture plate (200 mL) with
either lipopolysaccharide (1 mg·mL-1) alone or with
lipopolysaccharide (1 mg·mL-1) and cucurbitacin R
(10–100 mM) for 24 h. The cells were lysed with a
specific lysis buffer, and the resulting cell lysis was
then collected and assayed for interleukin-1b by use
of a specific enzyme immunoassay kit (eBioscience,
San Diego, CA, USA), used according to the manu-
facturer’s instructions.
Hoechst staining
Cells were grown on chamber slides and were either
left untreated or were treated with cucurbitacin R as
indicated. The cells were then fixed in a solution of
methanol-acetic acid (95:5) for 20 min at -20°C.
The slides were washed with phosphate-buffered
saline and incubated with Hoechst 3324 at 37°C to
stain the DNA. Samples were then examined with a
fluorescent microscope; the images were acquired
with a SPOT CCD camera (Nikon, Tokyo, Japan).
Results
Cucurbitacin R produced apoptosis in RAW
264.7 cells
To evaluate the effect of the anti-inflammatory drug
cucurbitacin R (Figure 1) in RAW 264.7 macrophages,
the cells were treated with the test compound
(100 mM) and cells were collected by means of cell
BJPCucurbitacin R induces apoptosis
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cycle analysis at different times after lipopolysaccha-
ride stimulation. Not only did cucurbitacin R arrest
the cell cycle in the G2/M phase starting at 12 h, but
it consequently produced an increase in the subG0
population corresponding to apoptotic cells at 18 h
(Figure 2A). These effects were observed only when
the cells were treated with both lipopolysaccharide +
cucurbitacin R; macrophages treated only with
cucurbitacin R (100 mM) underwent neither apopto-
sis nor cell cycle arrest. The apoptotic process was
confirmed by the DNA fragmentation assay. We
found that only after the co-treatment of cells with
lipopolysaccharide + cucurbitacin R was apoptosis
visible at 18 and 24 h later (Figure 2B). To corroborate
these data and evaluate how cucurbitacin R produced
the cell cycle arrest, we tested the levels of cyclin A1,
cyclin B1, cyclin D2, and cyclin E. While all the cyclin
levels diminished at 18 and 24 h after treatment, the
expression of cyclin D2 increased at 12 h (data not
shown). These effects correlate with the reduction of
cyclin levels in the apoptotic process.
In the annexin V assay corresponding to phos-
phatidylserine externalization, cucurbitacin R at
100 mM led to 51% of the cells being apoptotic-
necrotic cells (Figure 3A). This value was reduced to
19% when cells were treated with cucurbitacin R at
12.5 mM (Table 1). The concentration-dependent
apoptotic effect of cucurbitacin R was confirmed by
the DNA fragmentation assay and propidium iodide
staining (Figure 3C,D), in which the major apop-
totic effect occurred at concentrations of 50 and
100 mM; at the latter concentration, the apoptotic
bodies were actually visible at 24 h (Figure 4).
To determine how the apoptotic pathway is regu-
lated, we treated RAW macrophages with cucurbita-
cin R at 100 mM and collected cell extracts at
different time points. The apoptotic death produced
by cucurbitacin R induced the expression of p53
(Figure 5), which is mainly responsible for the arrest
of the cell cycle and regulator apoptosis. In addition,
cucurbitacin R also induced the production of the
apoptotic protein p21, which is also involved in cell
cycle arrest. Interestingly, whereas Bax was left
unregulated, Bcl-2 was down-regulated when the
RAW 264.7 macrophages were treated with cucurbi-
tacin R (Figure 5), producing a destabilization of the
8 h 12 h 18 h 24 hLPS 0 h
CucurbitacinR – 
CucurbitacinR +
Cucurbitacin 
LPS 
Hours
A
B
0 0 24 24 8 12 18 24 8 12 18 24
– – + – + + + + + + + +
– + – + – – – – + + + +
Figure 2
Cell cycle evolution after lipopolysaccharide (LPS) stimulation. (A) Inhibition of G0/G1 phase, G2/M arrest and apoptosis in cucurbitacin R-treated
cells. Plots were obtained with propidium iodide staining at different times after cucurbitacin R (100 mM) treatment with or without LPS
stimulation on RAW 264.7 macrophages. (B) DNA was obtained as described in the Methods section and the isolated DNA run on agarose gel
(1.5%). DNA fragmentation was observed 18 and 24 h after cucurbitacin R treatment with LPS. Figures are representative of three experiments
performed with similar results.
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Figure 3
Cucurbitacin R induced apoptosis in RAW 264.7 cells in a concentration-dependent manner. Cells were treated for 24 h with cucurbitacin R
(12.5–100 mM) after LPS stimulation. (A) Annexin V apoptosis assay. (B) Mitochondrial membrane potential assay. Cells were treated with
cucurbitacin R at various concentrations for 18 h and apoptotic cells, apoptotic-necrotic cells, and necrotic cells were examined with annexin V
or dihidrorodamine 123 and propidium iodide binding as described in the Methods section. (C) Plots were obtained with propidium iodide
staining after cucurbitacin R treatment at different concentrations (12.5–100 mM). (D) DNA fragmentation assay in RAW 264.7 cells. Figures are
representative of three experiments performed with similar results.
Table 1
Annexin V staining showed that cucurbitacin R produced apoptosis in RAW 264.7 cells in a concentration-dependent manner
Viable
cells %
Apoptotic
cells %
Apoptotic-necrotic
cells %
Necrotic
cells %
Blank 95  3 0  2 0  3 4  1
LPS 94  5 5  4 0  1 1  1
LPS + cucurbitacin R 100 mM 40  10 0  12 51  1 9  3
LPS + cucurbitacin R 50 mM 56  8 41  4 3  2 3  2
LPS + cucurbitacin R 25 mM 69  3 28  3 1  1 3  2
LPS + cucurbitacin R 12.5 mM 79  10 19  3 3  2 1  2
Cells were treated for 24 h with cucurbitacin R (12.5-100 mM) after LPS stimulation. Cells were collected and processed as described in
Methods. Data are an average of three independent experiments.
LPS, lipopolysaccharide.
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mitochondrial membrane potential, as measured by
dihydrorhodamine 123. This dye is the reduced
form of rhodamine 123, which is a commonly used
fluorescent mitochondrial dye. Dihydrorhodamine
123 itself is non-fluorescent, but it readily enters
most of the cells and is oxidized by cellular redox
systems to the fluorescent rhodamine 123 that accu-
mulates in mitochondrial membranes. When the
mitochondrial membrane potential is compro-
mised, the cell is not able to oxidize this compound.
As shown in Figure 3B, the fluorescence levels
of dihydrorhodamine 123 were reduced in the
cucurbitacin R-treated cells. These reduced values
are accompanied by higher levels of propipium
iodide staining, corresponding to apoptotic-necrotic
cells.
The intrinsic apoptotic pathway was confirmed
by caspase-9 Western blot. Upon apoptotic
stimulation, the mitochondrial membrane poten-
tial is destabilized and the cytochrome c released
from mitochondria associates with the 47 kDa
procaspase-9/Apaf 1 (Li et al., 1997). This complex
processes procaspase-9 into a large active fragment
(35 or 17 kDa). As expected, we were able to
detect the active form at 35 kDa of caspase-9 at 18
and 24 h after lipopolysaccharide stimulation in
the presence of cucurbitacin R 100 mM. We
checked for different effector caspases and the
active fragments, like caspase-3, cleaved caspase-3
fragment p17 and cleaved caspase-1 fragment p10.
As shown in Figure 5, we detected the active frag-
ment of caspase-3 at the later time points after
cucurbitacin R treatment. Surprisingly, we could
detect an increase in the levels of active caspase-1
(p10), and this correlated with lower levels of
Bcl-2.
A
C
B
D
Figure 4
Apoptotic effect of cucurbitacin R in RAW 264.7 cells. Cells were treated for 24 h with cucurbitacin R (100 mM). Cells were fixed with
methanol-acetic acid (95:5) and stained with Hoechst 3324. White arrows indicate that the cell cycle stopped in the G2/M phase; red arrows
indicate apoptotic cells. (A) Blank group, without stimulation or cucurbitacin R treatment; (B) cucurbitacin R-blank group, treated with
cucurbitacin but without stimulation with lipopolysaccharide (LPS); (C) control group, LPS-stimulated cells without cucurbitacin R treatment; (D)
cells stimulated with LPS and treated with cucurbitacin R. White arrows indicate cells that were arrested in the G2/M phase. Red arrows indicate
apoptotic cells. Figures are representative of two experiments performed with similar results.
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Cucurbitacin R-activated caspase-1 and
interleukin-1b release
As the cleavage of interleukin-1b is a good measure
of caspase-1 activation, we measured the levels of
this cytokine by different techniques. Firstly, we per-
formed Western blot on the extracts and superna-
tants of cucurbitacin-treated cells. Whereas in
lipopolysaccharide-treated cells, we detected the
inactive form of interleukin-1b and only low levels
of the cleaved form 17 kDa, in the cucurbitacin-
treated cells, we detected mainly the cleaved form of
interleukin-1b, at the different time points after acti-
vation of the apoptotic pathway (Figure 6A). We
also subjected the cell culture supernatants to
Western blot analysis of interleukin-1b. As expected,
we detected higher levels of interleukin-1b in the
cell supernatants treated with cucurbitacin R.
Secondly, we performed ELISA of interleukin-1b.
Thus, various concentrations of cucurbitacin R
(100–12.5 mM) were incubated with cells for 1 h and
then stimulated for 24 h. When cucurbitacin R was
used at apoptotic concentrations, the levels of
interleukin-1b were higher than in the control
(lipopolysaccharide-stimulated cells) (Figure 6B).
We went on to determine the interleukin-1b levels
in macrophages treated with cucurbitacin R
(100 mM) at different times. An increase in
interleukin-1b levels occurred at both 18 and 24 h,
times at which cucurbitacin R 100 mM was found to
induce apoptosis in RAW 264.7 macrophages
(Figure 6D). This correlation between interleukin-1b
levels and apoptosis was also found in human lym-
phocytes (data not shown).
To confirm the stimulatant effect of cucurbitacin
R on interleukin-1b levels and to determine whether
this effect occurs at the transcriptional level, qRT-
PCR analyses were performed. The total RNA
obtained from RAW 264.7 macrophages was used to
estimate the mRNA level by use of qRT-PCR.
Whereas LPS treatment increased the levels of
interleukin-1b mRNA, the cucurbitacin R (100 mM)
treatment in lipopolysaccharide-treated cells did not
change the mRNA levels of interleukin-1b, which
indicates that the over-release of interleukin-1b did
not occur at the transcriptional level. Consequently,
the maturation of this protein was over-activated.
We confirmed the effect of cucurbitacin R on the
activity of caspase-1 as well as on that of the effector
caspase-3 by use of fluorogenic substrates. Although
cucurbitacin R alone, at a concentration of 100 mM,
stimulated the activity of both caspase-1 and
caspase-3, when combined with lipopolysaccharide
I produced even higher levels of activity (Figure 6E).
Over-expression of Bcl-2 inhibited
cucurbitacin R-induced apoptosis and
interleukin-1b levels
To determine whether Bcl-2 and the plasminogen
activator (PAI)-2 regulated cucurbitacin R-induced
apoptosis and the over-expression of interleukin-1b,
we produced two stably transfected cell lines with
the Bcl-2 and PAI-2 expression plasmid. In addition,
we silenced caspase-1 and NALP1 with specific
siRNA (Figure 7C) to examine their role in both the
apoptotic process and interleukin-1b release.
Whereas altering PAI-2 expression or silencing
NALP1 or caspase-1 did not change the apoptotic
levels in cells treated with cucurbitacin R, RAW-Bcl-2
was found to be resistant to cucurbitacin R-induced
apoptosis (Figure 7A). In addition, the levels of
interleukin-1b in RAW-Bcl-2 were clearly diminished
in both the lipopolysaccharide-treated cells and
cucurbitacin R plus lipopolysaccharide-treated cells
(Figure 7B). As expected, caspase-1 silencing reduced
the levels of interleukin-1b in the cells as this
caspase is required for the processing of interleukin-
1b. In addition, PAI-2 expression did not affect
either the pro-apoptotic properties or the
interleukin-1b levels in cucurbitacin R-induced
Figure 5
Cucurbitacin R modulates the expression of proteins implicated in
apoptosis. RAW macrophages were treated with cucurbitacin R
(100 mM) at different times and then expression of p53, p21, Bcl-2,
Bax, cleaved-caspase-1 p10 subunit, caspase-9, cleaved caspase-3
p17 subunit and caspase-3 were determined with the aid of Western
blot techniques. b-Actin was used as a control. Figures are represen-
tative of two experiments performed with similar results. LPS,
lipopolyysaccharide.
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Figure 6
Cucurbitacin R treatment produced an increase in the release of interleukin-1b (IL-1b) in RAW 264.7 macrophages due to an increase in caspase-1
activity. (A) Western blot analysis on RAW macrophages cell extracts and cells supernatants of IL-1b. Cells were treated with cucurbitacin R
(100 mM) and lipopolyysaccharide (LPS) for different times and IL-1b levels were determined in cell lysates or supernatants as described in the
Methods section. (B) Cells were treated with cucurbitacin R (6.25–100 mM) or dexamethasone (10 mM) for 24 h and IL-1b levels were determined
in cell lysates as described in the Methods section. (C) Real time reverse transcription-polymerase chain reaction (RT-PCR). RAWmacrophages were
treated with cucurbitacin R (100 mM) and LPS. Cells were collected after 8 h of LPS stimulation and real time RT-PCR were carried out as described
in Methods. (D) Time course effect of cucurbitacin R in LPS stimulated RAW 264.7 cells. Columns represent cytokine production in pg mL-1 in the
presence or absence of test compounds with SEM and statistical significance: blank (untreated cells), control (LPS-stimulated cells). (E) Caspase
activity in cucurbitacin R-treated cells. Cells were treated with cucurbitacin R 100 mM with or without LPS for 24 h and cell lysates were incubated
with respective caspase-1 and caspase-3 fluorometric substrates for 2 h. The vertical lines indicate the SEM. Statistically significant difference with
respect to the control is expressed as **P < 0.01 (Dunnett’s t-test). Figures are representative of three experiments performed with similar results.
BJP JM Escandell et al.
1852 British Journal of Pharmacology (2010) 160 1844–1856
apoptosis. Moreover, cucurbitacin R did not affect
NF-kB activity (data not shown; Escandell et al.,
2006).
Discussion
Cucurbitacins are natural products known to have
anti-inflammatory and anti-cancer properties. We
have previously reported on the anti-arthritic and
anti-inflammatory effects of two such compounds,
cucurbitacin R and dihydrocucurbitacin B, along
with their effect on the cell cycle of human lympho-
cytes. In previous experiments, however, under the
experimental condition used, neither compound
was found to induce apoptosis (Recio et al., 2004;
Escandell et al., 2006; 2007a,b).
Recently, however, we demonstrated the apop-
totic effect of cucurbitacin R on colon cancer cells
(Escandell et al., 2008). In the present study, we have
examined the apoptotic effect of cucurbitacin R on
murine macrophages RAW 264.7, its effect on the
release of interleukin-1b and its possible regulation
by the anti-apoptotic protein Bcl-2. Apoptosis is one
of the mechanisms that living organisms have for
removing cells from tissues in a deliberate and sys-
tematic manner. It is brought on by different cell
signals and regulated by various pro- or anti-
Figure 7
Effect of Bcl-2, PAI-2, NALP1 and caspase-1 on cucurbitacin R-induced apoptosis. (A) RAW 264.7 cells, RAW- Bcl-2 cells, NALP1 silenced cells,
RAW-PAI-2 cells and caspase-1 silenced cells were treated with cucurbitacin R (100 mM) and lipopolyysaccharide (LPS) for 24 h and the levels of
apoptosis were measured by propidium iodide staining. (B) RAW 264.7 cells, RAW- Bcl-2 cells, RAW-PAI-2 cells, and caspase-1 silenced cells were
treated with cucurbitacin R (100 mM) and LPS for 24 h and the IL-1b levels were measured. (C) Western blots corresponding to caspase-1 silenced
cells, RAW-Bcl-2 cells and NALP1 silenced cells. Statistically significant difference with respect to the control is expressed as **P < 0.01 (Dunnett’s
t-test). Figures are representative of three experiments performed with similar results.
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apoptotic proteins such as caspases and the family of
Bcl proteins. Activation of inflammatory caspases
occurs upon assembly of the inflammasome (Marti-
non and Tschopp, 2004) or of the molecular platform
for the activation of pro-inflammatory caspases such
as caspase-1 (Petrilli et al., 2005). The inflammasome
system processes the cytoplasmatic pro- interleukin-
1b, which is transcriptionally regulated by NF-kB. As
a result, interleukin-1b is processed and released
during apoptosis (Hogquist et al., 1991; Martinon
and Tschopp, 2004). Because the anti-apoptotic pro-
teins Bcl-2 and Bcl-XL interact with NALP1, one of the
central proteins in the inflammasome complex, to
suppress caspase-1 and interleukin-1b production
(Petrilli et al., 2005; Bruey et al., 2007), we decided to
study the effect of a pro-apoptotic compound, cucur-
bitacin R, on the expression of both the anti-
apoptotic protein Bcl-2 and the pro-apoptotic
protein Bax. We also examined its role in the activa-
tion of caspase-1 and the release of interleukin-1b.
We found that when cucurbitacin R was applied to
RAW 264.7 cells, the production of interleukin-1b
clearly increased, as did apoptosis and cyclin D2
production. Other cyclins, in contrast, were reduced.
Indeed, several studies have indicated that
lipopolysaccharide induces the expression of cyclin
D2 in macrophages (Vadiveloo et al., 2000) while
other reports have implicated the over-expression of
cyclin D2 in the arrest of the cell cycle and apoptosis
(Banerji et al., 2001).
Cucurbitacin R down-regulated the expression
of the anti-apoptotic protein Bcl-2, whereas the
protein p53 was over-expressed 8, 12 and 18 h after
treatment. This transcription factor plays a signifi-
cant role in the regulation of the cell cycle to
prevent mutations and cancer (Harms and Chen,
2005), as well as to control the functions of p21. It
regulates the progression of the cell cycle, which
was clearly increased at 18 and 24 h as a conse-
quence of the increased p53 activity, in the S phase
(Gartel and Radhakrishnan, 2005). In our experi-
ments, the expression of the pro-apoptotic protein
Bax was not modified. The intrinsic pathway for
caspase activation in cells involves the participa-
tion of the mitochondria, with a change in the
mitochondrial membrane potential releasing
caspase-activating proteins such as cytochrome c
into the cytosol (St-Louis and Archambault, 2007).
In our experiments, when RAW 264.7 macrophages
were treated with cucurbitacin R at various concen-
trations, the mitochondrial membrane potential
was modified at 18 h, and caspase-9 and caspase-3
were activated. This result indicates that the mito-
chondrial apoptotic pathway is implicated in
cucurbitacin R-induced apoptosis in RAW 264.7
macrophages.
In their work, Bruey et al. (2007) demonstrated
the relationship between the Bcl-2 levels and the
inhibition of interleukin-1b. This effect is due to the
inhibition of the activation of NALP1, a protein that
constitutes part of the inflammosome, which acti-
vates caspase-1. In addition, Park et al. (2005)
showed that PAI-2 inhibited both apoptosis and
interleukin-1b secretion in Toll-like receptor 4
stimulated cells. Using stably transfected cell lines
which included Bcl-2 and PAI-2 expression plasmids
and which had been silenced for caspase-1 activity,
we found that neither PAI-2 expression nor
caspase-1 silencing or NALP1 silencing produced a
change in the apoptotic levels of cells that had been
treated with cucurbitacin R. In contrast, the RAW-
Bcl-2 cells were resistant to cucurbitacin R-induced
apoptosis. This indicates that Bcl-2 plays an impor-
tant role in the apoptotic mechanism of cucurbita-
cin R. In addition, the level of interleukin-1b in
RAW-Bcl-2 cells was clearly lower in the treated cells.
Moreover, neither caspase-1 silenced cells nor PAI-2
over-expressed cells were found to undergo any
change in the apoptotic levels produced by cucur-
bitacin R. These results show that Bcl-2, but not
PAI-2 or caspase-1, regulate both apoptosis and
interleukin-1b secretion in cucurbitacin R-induced
apoptosis and that there is a clear correlation
between interleukin-1b levels and apoptosis.
As noted above, NF-kB regulates both
interleukin-1b expression and interleukin-1b pro-
duction during apoptosis (Martinon and Tschopp,
2004). One possibility that has been proposed for
reducing NF-kB activation is that of blocking IKKb,
one of the two catalytic subunits of the IKK complex
(Karin et al., 2004). IKKb activity is required for the
activation of a severe inflammatory reaction in
response to ischaemia-reperfusion and for the pro-
tection of a large number of different cell types from
apoptosis. This allows for the use of specific inhibi-
tors as potential anti-inflammatory agents (Karin
et al., 2004). Various drugs have been described as
inhibitors of IKKb kinase activity, including natural
products such as flavonoids and resveratrol. Because
IKKb inhibition increases caspase-1 activation and
interleukin-1b production, Greten et al., (2007) con-
sider NF-kB to be a negative regulator of
interleukin-1b secretion. However, in our study, the
inhibition of IKKb had no effect (data not shown;
Escandell et al., 2006).
In conclusion, we have demonstrated that cucur-
bitacin R produces apoptosis in lipopolysaccharide-
activated RAW 264.7 macrophages. This effect is
regulated by Bcl-2 whereas Bax, caspase-1, NALP1
and PAI-2 do not seem to be involved. Moreover,
there is a clear correlation between interleukin-1b
levels produced by the cells and the apoptotic
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effects. In addition, Bcl-2 was found to act as a
negative regulator of interleukin-1b secretion in
cucurbitacin R-induced apoptosis. Taken together,
these results allow us to describe a new apoptotic
process in which interleukin-1b release is directly
regulated by the Bcl-2 status, which contributes to
the evidence that apoptotic processes do not induce
inflammation.
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